Correspondence 0001079973-22-001563 from OPGEN INC (OPGN) (CIK 0001293818) (OPGN)
OPGEN INC (OPGN) (CIK 0001293818)
Date: Dec. 16, 2022 · CIK: 0001293818 · Accession: 0001079973-22-001563
AI Filing Summary & Sentiment
File numbers found in text: 333-268648
Referenced dates: December 15, 2022
Letter
Correspondence
Peter Jaslow Tel: 215.864.8737 Fax: 215.864.8999 jaslowp@ballardspahr.com
December 16, 2022
By EDGAR
Division of Corporation Finance
Office of Industrial Applications and Services
United States Securities and Exchange Commission
Washington, D.C. 20549
Attn: Sean Healy
Dorrie Yale
Re: OpGen, Inc.
Registration Statement on Form S-1
Filed December 1, 2022
File No. 333-268648
Ladies and Gentlemen:
This letter responds to the Staff’s comment letter dated December 15, 2022 to Oliver Schacht, the Chief Executive Officer of OpGen, Inc. (the “Company”), regarding the above-captioned Form S-1. For your convenience, the Staff’s comment has been reproduced, followed by the Company’s response to such comment. The Company has elected to provide this response letter prior to filing its amended and restated Form S-1 pending resolution of the response to the below comment.
General
1. We refer to your disclosure in the Plan of Distribution section that you will enter into a securities purchase agreement with "institutional investors," but that other investors shall rely solely on the prospectus in connection with purchasing securities in this offering. Please explain to us why there is disparate treatment of different investors in the same offering.
RESPONSE: The Company will file an Amended and Restated Registration Statement on Form S-1 (The “Form S-1/A”) to revise the referenced disclosure in the Plan of Distribution section as follows:
“We may will enter into a securities purchase agreement directly with certain the institutional investors who elect to enter into such agreement to purchase our securities in the offering., at the investor’s option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering.”
In addition, the Company advises the Staff that it will not distinguish between institutional investors and other investors in the offering, and as such, all potential investors will be offered the same opportunity to enter into a securities purchase agreement for purchase of securities in the offering. Accordingly, the Company does not believe that different investors will receive disparate treatment in the offering.
We acknowledge the Company’s and its management’s responsibility for the accuracy and adequacy of the Company’s disclosures. Please contact me at (215) 864-8737 with any questions or comments you may have regarding this response. The Company’s management is available for discussion as needed to resolve these comments.
Very truly yours,
/s/ Peter Jaslow
Show Raw Text
CORRESP
1
filename1.htm
Correspondence
Peter Jaslow
Tel: 215.864.8737
Fax: 215.864.8999
jaslowp@ballardspahr.com
December 16, 2022
By EDGAR
Division
of Corporation Finance
Office of Industrial Applications and Services
United States Securities and Exchange Commission
Washington, D.C. 20549
Attn: Sean Healy
Dorrie Yale
Re: OpGen,
Inc.
Registration Statement on Form S-1
Filed December 1, 2022
File No. 333-268648
Ladies and Gentlemen:
This letter responds to the
Staff’s comment letter dated December 15, 2022 to Oliver Schacht, the Chief Executive Officer of OpGen, Inc. (the “Company”),
regarding the above-captioned Form S-1. For your convenience, the Staff’s comment has been reproduced, followed by the Company’s
response to such comment. The Company has elected to provide this response letter prior to filing its amended and restated Form S-1 pending
resolution of the response to the below comment.
General
1. We refer to your disclosure in the
Plan of Distribution section that you will enter into a securities purchase agreement with
"institutional investors," but that other investors shall rely solely on the prospectus
in connection with purchasing securities in this offering. Please explain to us why there
is disparate treatment of different investors in the same offering.
RESPONSE: The Company will file
an Amended and Restated Registration Statement on Form S-1 (The “Form S-1/A”) to revise the referenced disclosure in the
Plan of Distribution section as follows:
“We may will
enter into a securities purchase agreement directly with certain the institutional
investors who elect to enter into such agreement to purchase our securities in the offering., at the investor’s
option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely
on this prospectus in connection with the purchase of our securities in this offering.”
In addition, the Company advises
the Staff that it will not distinguish between institutional investors and other investors in the offering, and as such, all potential
investors will be offered the same opportunity to enter into a securities purchase agreement for purchase of securities in the offering.
Accordingly, the Company does not believe that different investors will receive disparate treatment in the offering.
We acknowledge the Company’s
and its management’s responsibility for the accuracy and adequacy of the Company’s disclosures. Please contact me at (215)
864-8737 with any questions or comments you may have regarding this response. The Company’s management is available for discussion
as needed to resolve these comments.
Very truly yours,
/s/ Peter Jaslow
Peter Jaslow
PJ/mbl